StocktoriaBioAtla, Inc. BCAB
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-164.82
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | — | — | — | — | $300,000 |
| Operating income | -$59.3M | -$73.9M | -$129.7M | -$108.1M | -$96.4M |
| Net income | -$59.6M | -$69.8M | -$123.5M | -$106.5M | -$95.4M |
| Operating cash flow | -$48.2M | -$71.9M | -$104.0M | -$90.4M | -$62.2M |
| Total assets | $13.8M | $52.4M | $119.7M | $225.7M | $254.4M |
| Total liabilities | $50.0M | $38.2M | $49.0M | $45.4M | $43.6M |
| Shareholders' equity | -$36.2M | $14.3M | $70.7M | $180.3M | $210.8M |
| Ratios | |||||
| Operating margin | — | — | — | — | -32146.7% |
| Net margin | — | — | — | — | -31800.7% |
| Return on assets | -431.1% | -133.1% | -103.2% | -47.2% | -37.5% |
| Return on equity | 164.7% | -489.1% | -174.7% | -59.0% | -45.3% |
| Current ratio | 0.37 | 3.52 | 4.11 | 9.53 | 12.48 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -164.82 (distress)
- Working capital / assets -1.006
- Retained earnings / assets -39.46
- EBIT / assets -4.289
- Equity / liabilities -0.724
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001826892 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.